News archive
All the latest on Lundbeck
Keep updated on our latest corporate releases, press releases, and features.
Filter within articles
| Type | Title | Published |
|---|---|---|
| Press Release | Lundbeck and OpenAI join forces to unlock innovation and boost productivity | Oct 27, 2025 |
| Press Release | Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions | Oct 20, 2025 |
| Press Release | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Oct 13, 2025 |
| Press Release | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 | Oct 2, 2025 |
| Corporate Release | Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD | Sep 20, 2025 |
| Press Release | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine | Sep 11, 2025 |
| Press Release | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 | Sep 9, 2025 |
| Press Release | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy | Aug 25, 2025 |
| Corporate Release | Guidance raised based on solid H1 results and continued strong expectations for the full year 2025 | Aug 13, 2025 |
| Corporate Release | Lundbeck raises financial guidance for 2025 | Aug 13, 2025 |
Disclaimer
In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request. Contact us here.
Company announcements
Thanks for signing up.
Investors
Detailed information related to Lundbeck’s financial performance.
At a glance
A quick look into Lundbeck’s key facts and figures.
Organisation and ownership
Lundbeck is publicly listed with the Lundbeck Foundation as its main shareholder.